Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
30. März 2021 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of...
Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
01. März 2021 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast...
Allakos Appoints Natalie Holles to its Board of Directors
22. Dezember 2020 16:05 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related...
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
09. November 2020 08:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast...
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
02. November 2020 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related...
Allakos Announces Pricing of Public Offering of Common Stock
28. Oktober 2020 20:20 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
27. Oktober 2020 19:56 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast...
Allakos Announces Proposed Public Offering of Common Stock
27. Oktober 2020 16:09 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
26. Oktober 2020 07:00 ET
|
Allakos Inc.
-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Management to host conference call and...
Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
26. Oktober 2020 07:00 ET
|
Allakos Inc.
-- 45% (181/405) of symptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis -- --...